SOMAÍ Pharmaceuticals

Home
SOMAÍ Pharmaceuticals

Somai is fast becoming one of the most recognized and well-developed pharmaceutical brands in the EU.

A leading EU-GMP European vertically integrated Multi-Country Operator (MCO) company with a global footprint of distribution for the largest and most advanced EU GMP-certified cannabinoid-containing pharmaceutical extract portfolio Somai Pharmaceuticals LTD is a European pharmaceutical and biotech company centered on manufacturing in Lisbon, Portugal and distribution of EU GMP-certified cannabinoid-containing pharmaceuticals throughout the European Union and globally. Somai emphasizes scientific pharmacology applications with EU-GMP standards to deliver treatments to the endocannabinoid system, effectively and with consistency across all markets. Somai's product development knowledge was honed in the competitive American market, and is the largest and most advanced cannabinoid manufacturing facility across legal European markets producing medicines products and registered API's. Somai has brought together an all-star team of scientists and KOL's from around the world with various clinical experiences to guide Somai's product development and acceptance globally. Somai stresses education and continual R&D, which started from the USA as transformative developments, to help EU doctors and patients properly diagnose and treat the individual indications by providing variable dosage choices. Somai’s primary goal is producing the most advanced products with the most innovative delivery methods to create maximum bioavailability and healing for patients. As a global biotech player concentrating on cannabinoids, Somai has a unique pipeline of current and future products that will be on the market starting in late 2022. They already boast one of the largest IP (Intellectual Property) vaults of APIs that weren’t accessible to Europe until recently. Somai’s near term products conform to the highest standards of herbal medicine (ACM) and specialized cannabinoid API’s for R&D, but also keeps a steady eye on the horizon of future clinical trials for their proprietary pipeline, setting it up to be well positioned for the next decade.

28/10/2025

airobrands official, a U.S. multi-state CPG company focused on proprietary cannabis products, in partnership with Jupiter Research LLC, has received regulatory approval for its CE-marked Class IIa medical handheld liquid inhalation device, the Airo Medical Inhalation System, across Europe. This planned launch will introduce the second EU-certified device of its kind, designed specifically for the delivery of cannabinoid-based medicines under strict medical standards.

This milestone will mark the entry of a precision-engineered device into regulated medical markets, supported by a strategic partnership with SOMAÍ, which will manufacture EU-GMP inhalation oils and serve as the exclusive global distributor for the system’s cartridge line and API’s.

The Airo medical inhalation device is built in full compliance with EU Medical Device Regulation, offers a rechargeable, CE-certified platform engineered for precision, safety, and regulatory integrity. Its ergonomically rounded design ensures comfort and ease of use—critical factors for patients managing chronic therapies. This user-friendly form factor will not only support better patient adherence but will also allow for discreet, consistent dosing with confidence.

Learn more about the product: https://airobrands.com/international/

Read the full news here: https://www.einpresswire.com/article/862201259/airo-brands-announces-ce-certified-medical-inhalation-device-in-partnership-with-soma

22/10/2025

🔹 Inhalation as Medication: Fast, Precise, Effective

When it comes to cannabinoid-based treatment, inhalation offers unique therapeutic advantages.

🌀 Faster onset of action — effects can begin within minutes
🌀 Greater dose control — ideal for titration and managing breakthrough symptoms
🌀 Higher bioavailability — more of the active ingredients reach systemic circulation
🌀 Non-invasive administration — no need for swallowing or digestion

At SOMAÍ, we are committed to advancing inhalation formats that meet the highest pharmaceutical standards — combining patient-friendly delivery with clinical precision.

💡 From fast-acting relief to tailored treatment options, inhalation is helping redefine how cannabis-based medicines are prescribed — and experienced.

16/10/2025

We recently attended the Women & Medicinal Cannabis Forum — an inspiring discussion on cannabis in women’s health, from endometriosis and menopause to chronic pain, anxiety, and insomnia.

Thank you to keynote speaker Rachel Payne MP and panellists Alice Davy, Tegan Scates, and Lisa Nguyen for sharing their insights.

The SOMAÍ team was proud to be there, supporting education that reduces stigma and improves patient access.

14/10/2025

🔹 Not all extracts are made the same.

At SOMAÍ, we refine every detail — removing impurities and preserving only what matters.
Our purification process ensures clean, stable, and pharmaceutical-grade cannabis extracts — setting the standard for quality and consistency in medicine.

💙 Refined in purity and result.

09/10/2025

In an industry defined by local operators struggling to stay afloat and confined within their borders, Michael Sassano, founder and CEO of SOMAÍ, has created a blueprint for scaling cannabis worldwide with pharmaceutical discipline and regulatory agility. With headquarters in Lisbon and operations in 12 countries today, SOMAÍ is preparing to reach 18 by year’s end.

“Every new country is like starting a company from scratch,” Sassano said in an interview. “You have to understand not only the national regulations but also how local medical communities perceive cannabis, how prescriptions are written, and what distributors are required to do. There’s no one-size-fits-all approach.”

Read the full article about SOMAÍ by Pam Chmiel here: https://cannabisindustryjournal.com/feature_article/taking-cannabis-global-inside-somai-pharmaceuticals-multi-country-strategy/

08/10/2025

🔹 Not all essentials are this pure.

At SOMAÍ, purity isn’t just a standard — it’s a science.

The difference between what’s acceptable and what’s exceptional is clear.

Our EU-GMP-certified purification process is designed to remove impurities with precision, delivering cannabinoid-based medicines that are clean, stable, and consistent.

🌿 In a sea of murky formulations, SOMAÍ makes essentials refined — in purity and in result.
Curious how we do it? Check out our peer‑reviewed study in collaboration with Lusófona University, which outlines best practices in full-spectrum cannabis oil production.

🔗 Read the study: https://somaipharma.eu/news/somai-and-lusofona-university-publish-peer-reviewed-study-showcasing-best-practices-in-full-spectrum-cannabis-oil-production/

07/10/2025

Today, the Spanish Council of Ministers has approved a Royal Decree regulating the medical use of cannabis through standardized preparations.

The regulation aims to provide a therapeutic alternative for patients who do not respond to conventional treatments, particularly those suffering from chronic refractory pain, severe epilepsy, or spasticity associated with multiple sclerosis.

“The approval of Spain’s medical cannabis Royal Decree is a long-awaited and important milestone,” said Michael Sassano, Founder and Interim CEO of SOMAÍ. “While it marks the beginning of patient access in Spain, it sets the foundation for a structured, evidence-based framework that can evolve with science and experience. As one of Europe’s leading EU-GMP extract manufacturers, SOMAÍ is ready to support this new chapter by sharing expertise, ensuring pharmaceutical consistency, and helping healthcare professionals gain confidence in cannabinoid-based therapies.”

Read the full text: https://www.sanidad.gob.es/gabinete/notasPrensa.do?id=6761

03/10/2025

🔹 From Intern to Industry Scientist – Milene’s Journey at SOMAÍ

We’re incredibly proud to celebrate Milene Costa, who successfully defended her Master’s thesis titled:
“Development and Validation of a Method for the Analysis of Terpenes in Cannabis sativa” – earning an outstanding 18/20!

Milene’s journey from intern to a full member of our Quality Control team is a shining example of SOMAÍ’s commitment to nurturing young professionals and creating real growth opportunities in the pharmaceutical cannabis industry.

We believe in investing in people just as much as in innovation – and Milene’s achievement is proof that with the right support, young talent can thrive.

02/10/2025

🔹 We’re hiring this October!

Join one of Europe’s leading EU-GMP-certified cannabis pharmaceutical companies and grow your career with SOMAÍ.

We’re looking for talented professionals to join our expanding team in Portugal:

📍 Carregado, Lisbon
• Accounting Assistant
• Accounts Receivable
• Controller
• Estágio IT - IEFP - Medida Estágio IEFP
• Operador Armazém
• Project Manager
• Quality Control Assistant
• Regulatory Affairs Specialist
• Supply Chain Specialist

📍 Rio de Mouro, Sintra
• Office Assistant

If you’re passionate, proactive, and ready to make an impact in a fast-growing industry — we’d love to hear from you.
👉 Apply now at somaipharma.eu/careers
📩 Or reach out directly: rh@somaipharma.eu

29/09/2025

We’re excited to welcome Thomas Kingi to the SOMAÍ Australia team!

With over 16 years’ experience in warehousing and logistics, Kingi brings deep expertise in end-to-end delivery, process optimisation, and sustainable growth.

He’s passionate about identifying gaps, implementing improvements, and building strong relationships across the full operational pathway. We’re thrilled to have him on board as we continue to expand our impact in Australia.

26/09/2025

The new age of cannabis dosing with gummies is sweeping the globe, but a quality crisis threatens the industry’s pharmaceutical credibility. What started in Australia has quickly moved to the UK and now Germany, where EU-GMP cannabis gummies struggle to compete against a flood of inferior products rushing to market.

Read the latest article by Sassano published in Krautinvest: https://krautinvest.de/eu-gmp-cannabis-gummies-face-uphill-battle-against-low-quality-market-flood/

24/09/2025

🔹 Catch Michael Sassano at PTMC 2025!

Tomorrow, SOMAÍ Founder Michael Sassano will be speaking at the Portugal Medical Cannabis (PTMC) conference in Lisbon, joining the roundtable:

“Building a Successful Cannabis Company: How to Attract Investment and Achieve ROI”

With decades of experience scaling cannabis ventures from the U.S. to Europe, Michael will share practical insights into navigating capital markets, building cross-border operations, and what real ROI looks like in today’s evolving cannabis landscape.

📍 PTMC – Portugal Medical Cannabis
📅 September 25
🕑 Roundtable time: 12:00
💬 Topic: “Building a successful cannabis company: How to attract investment and achieve ROI”

Looking forward to insightful discussions with industry leaders, regulators, and innovators at one of Europe’s most intimate and high-level cannabis events.

Address

Website

http://www.somaipharma.eu/

Alerts

Be the first to know and let us send you an email when SOMAÍ Pharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to SOMAÍ Pharmaceuticals:

Want your practice to be the top-listed Clinic?

Country:

City: